Q-omics provides the consensus-scored TRAV31 profile across patient tissues and cancer cell-line models. TRAV31 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TRAV31 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, TRAV31 RNA expression shows 7,358 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight READ, KIRC, and LAML as cancer lineages where TRAV31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV31 survival associations across molecular data types. TRAV31 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV31 RNA expression–survival associations across cancer types. High TRAV31 expression shows unfavorable associations in READ, CESC, GBM, STAD and BRCA, but favorable associations in LAML. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify READ as the clearest survival context for TRAV31 RNA expression.
This table summarizes TRAV31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV31 shows higher tumor expression in KIRC, KIRP and THCA. The KIRC box plot shows higher TRAV31 RNA expression in tumor versus normal tissue (log2 FC = +0.064, t-test p = .006).
This table shows molecular features associated with TRAV31 in patient tissues and cancer cell lines. In patient samples, TRAV31 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
